Skip to main content
Caplight Logo









Clear Crossing Biosciences

Clear Crossing Biosciences

Private
Portland, OregonHealthcare & Life Scienceshttps://clearcrossingbiosciences.com/

Last Round

Accelerator

May 1, 2024

Company Overview

Clear Crossing Biosciences is a biotechnology company that develops an endosomal release platform for targeted intracellular delivery of RNA therapeutics and therapeutic antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intracellular deliveryendosomal releasepeptide engineeringdrug delivery platformRNA therapeuticsendosomal escapebiomacromolecule deliverytherapeutic antibodiesdrug discoverybiotech R&Ddelivery techbio-deliverypeptide therapeuticsdrug formulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Clear Crossing Biosciences Comparables

Compare Clear Crossing Biosciences with similar companies based on industry and business-model similarity.

Clear Crossing Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Feldan Therapeutics
82%
Xelcis Bio, Inc.
82%
Sapreme Technologies BV
81%

Clear Crossing Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorMay 1, 2024

Key People

Founding team and executive leadership

Jean Summerton

Founder CEO, Clear Crossing Biosciences (formerly EndoRel Biosciences)

Founding Team

Clear Crossing Biosciences Investors

Notable investors and investment history

Clear Crossing Biosciences investors
InvestorRounds
Oregon Bioscience IncubatorAccelerator

Clear Crossing Biosciences Filings

Explore SEC and related filing metadata, where available.

Clear Crossing Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Clear Crossing Biosciences's valuation, stock price, and market status.

Is Clear Crossing Biosciences a public or private company?

Clear Crossing Biosciences is a private company.

What is the current stock price of Clear Crossing Biosciences?

Clear Crossing Biosciences is a private company with no public stock price. Caplight tracks Clear Crossing Biosciences's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Clear Crossing Biosciences worth (valuation)?

Valuation information for Clear Crossing Biosciences is not publicly available.

Can I buy Clear Crossing Biosciences stock?

Clear Crossing Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Clear Crossing Biosciences's last funding round?

Clear Crossing Biosciences's most recent funding round was Accelerator on May 1, 2024.

Who are the main investors in Clear Crossing Biosciences?

Key investors in Clear Crossing Biosciences include Oregon Bioscience Incubator.

Will Clear Crossing Biosciences IPO soon?

No public IPO plans have been announced for Clear Crossing Biosciences.

How can I track Clear Crossing Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Clear Crossing Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPortland, Oregon
Employee Range2
Year Founded2021
Last FundingMay 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?